Ivermectin as a Novel Therapy in COVID-19 Treatment

Phase 3CompletedNCT04403555

Tanta University164 enrolled

Overview

Efficacy of Ivermectin in COVID-19 treatment

Clinical Study Evaluating the Efficacy of Ivermectin in COVID-19 treatment

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

164

Conditions

COVID

Interventions

IvermectinDRUG

Ivermectin treatment

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * All Adult Patients aging from 20 to 65 years-old with COVID-19 confirmed by pharyngeal swab PCR. Exclusion Criteria: * Allergy or contraindication to the drugs used in the study. * Pregnant and lactating mothers. * Patients with cardiac problems.

Locations (1)

Sherief Abd-Elsalam

Tanta, Egypt

Outcomes

Primary Outcomes

The number of patients with mortality

Improvement of survival

Time frame: 1 month

Secondary Outcomes

Length of hospital stay

Effect on the length of hospital stay

Time frame: 1 month

The need for mechanical ventilation

Need for mechanical ventilation

Time frame: 1 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.